ProCE Banner Activity

CARISEL: Clinical Outcomes by Implementation Strategy of Patients Receiving LA CAB + RPV in European Healthcare Settings

Slideset Download
Conference Coverage

Long-acting cabotegravir plus rilpivirine was effective and well tolerated at 12 months regardless of implementation support in this phase IIIb study.

Released: October 26, 2022

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare